Traditional Chinese medicine-based drug delivery systems for anti-tumor therapies

Abstract

The treatment of tumors continues to be significantly challenging. The presence of multiple modalities, including surgery, radiation, chemotherapy and immunotherapy, the therapeutic outcomes remain limited and are often associated with adverse effects and inconsistent efficacy across cancer types. Recent studies have highlighted the potential of active components from traditional Chinese medicine (TCM) for their anti-cancer properties, which are attributable to multi-targeted mechanisms and broad pharmacological actions. Despite this potential, TCM-derived compounds are commonly limited by poor water solubility, low bioavailability, and suboptimal targeting. Currently, it is believed that advances in nanotechnology could address these limitations. Nanoparticles (NPs), which possess properties such as enhanced bioavailability, controlled release and precise targeting, have been used to improve the therapeutic efficacy of TCM components in cancer therapy. This review discusses the use of NPs for the delivery of active TCM compounds via organic-inorganic nanocarriers, highlighting innovative strategies that enhance the effectiveness of TCM-based anti-tumor components to provide insights into improving clinical outcomes while advancing the modernization and global application of TCM in oncology.

Keywords

Traditional Chinese medicine / Nano drug delivery systems / Organic-inorganic nanocarriers

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.

[2] Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-49.

[3] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.

[4] Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers[J]. Mol Biol Rep, 2023, 50(11): 9663-9676.

[5] Sun R, Dai J, Ling M, et al. Delivery of triptolide: a combination of traditional Chinese medicine and nanomedicine[J]. J Nanobiotechnol, 2022, 20(1): 194.

[6] Yang Z, Liao X, Lu Y, et al. Add-on therapy with traditional Chinese medicine improves outcomes and reduces adverse events in hepatocellular carcinoma: a meta-analysis of randomized controlled trials[J]. Evid Based Complement Alternat Med, 2017, 3428253.

[7] Xu W, Li B, Xu M, et al. Traditional Chinese medicine for precancerous lesions of gastric cancer: a review[J]. Biomed Pharmacother, 2022, 146: 112542.

[8] Kalepu S, Nekkanti V. Improved delivery of poorly soluble compounds using nanoparticle technology: a review[J]. Drug Deliv Transl Res, 2016, 6(3): 319-32.

[9] Wei D, Yang H, Zhang Y, et al. Nano-traditional Chinese medicine: a promising strategy and its recent advances[J]. J Mater Chem B, 2022, 10(16): 2973-94

[10] Ma Z, Zhang B, Fan Y, et al. Traditional Chinese medicine combined with hepatic targeted drug delivery systems: a new strategy for the treatment of liver diseases[J]. Biomed Pharmacother, 2019, 117: 109128.

[11] Wang M, Peng P, Chen Z, et al. Nanoparticle delivery of active traditional Chinese medicine ingredients: a new strategy for the treatment of liver cancer[J]. Curr Pharm Biotechnol, 2023, 24(13): 1630-1644.

[12] (a) Qiao L, Han M, Gao S, et al. Research progress on nanotechnology for delivery of active ingredients from traditional Chinese medicines[J]. J Mater Chem B, 2020, 8 (30): 6333-6351.

[13] (b) Liu YY Wang, X, Liu ML, et al. Chemical nature of metabolic activation of natural products in traditional Chinese medicines possibly associated with toxicities[J]. Acup and Herbal Med, 2024, 4 (2): 184-196.

[14] Amin M, Mohammad M, Saba D, et al. Nanocarriers call the last shot in the treatment of brain cancers[J]. Technol Cancer Res Treat, 2022, 21: 15330338221080974.

[15] Alqosaibi AI. Nanocarriers for anticancer drugs: challenges and perspectives[J]. Saudi J Biol Sci, 2022, 29(6): 103298.

[16] Hueppe N, Wurm FR, Landfester K. Nanocarriers with multiple cargo load-a comprehensive preparation guideline using orthogonal strategies[J]. Macromol Rapid Commun, 2023, 44(16): e2200611.

[17] Dahiya S, Dahiya R, Hernández E. Nanocarriers for anticancer drug targeting: recent trends and challenges[J]. Crit Rev Ther Drug Carrier Syst, 2021, 38(6): 49-103.

[18] Han R, He H, Lu Y, et al. Oral targeted drug delivery to post-gastrointestinal sites[J]. J Controlled Release, 2024, 370: 256-76.

[19] Fan YX, Jiang YL, Hao WF. Research progress on effective components and cultivation techniques of artemisia argyi[J]. SCAST, 2023, 44(11): 221-5.

[20] Assaf SM, Maaroof KT, Altaani BM, et al. Jojoba oil-based microemulsion for transdermal drug delivery[J]. Res Pharm Sci, 2021, 16(4): 326-40.

[21] Long Y, Xiang Y, Liu S, et al. Baicalin liposome alleviates lipopolysaccharide-induced acute lung injury in mice via inhibiting TLR4/JNK/ERK/NF-κB pathway[J]. Mediators Inflamm, 2020, 8414062.

[22] Li N, Feng L, Tan Y, et al. Preparation, characterization, pharmacokinetics and biodistribution of baicalin-loaded liposome on cerebral ischemia-reperfusion after i.v administration in Rats. [J]. Molecules, 2018, 23( 7): 1747.

[23] Chen Y, Wu Q, Zhang Z, et al. Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics[J]. Molecules, 2012, 17(5): 5972-5987.

[24] Zhai B, Wu Q, Wang W, et al. Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated β-elemene liposomes[J]. Cancer Biol Med, 2020, 17(1): 60-75.

[25] Cao J, Sun J, Wang X, et al. N-trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery[J]. Drug Dev Ind Pharm, 2009, 35(11): 1339-1347.

[26] Guo J, Zeng H, Shi X, et al. A CFH peptide-decorated liposomal oxymatrine inactivates cancer-associated fibroblasts of hepatocellular carcinoma through epithelial-mesenchymal transition reversion[J]. J Nanobiotechnol, 2022, 20(1): 114.

[27] Cao Y, Chen Z, Sun L, et al. Herb polysaccharide-based drug delivery system: fabrication, properties, and applications for immunotherapy[J]. Pharmaceutics, 2022, 14(8): 1703.

[28] Zhu T, Chen Z, Jiang G, et al. Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-Cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy[J]. ACS Nano, 2023, 17(17): 16770-16786.

[29] Jin SM, Lee SN, Kim JE, et al. Overcoming chemoimmunotherapy-induced immunosuppression by assemblable and depot forming immune modulating nanosuspension[J]. Adv Sci (Weinh), 2021, 8(19): e2102043.

[30] Wang Y, Lu HL, Liu YD, et al. Cryptotanshinone sensitizes antitumor effect of paclitaxel on tongue squamous cell carcinoma growth by inhibiting the JAK/STAT3 signaling pathway[J]. Biomed Pharmacother, 2017, 95: 1388-1396.

[31] Luo K, Yang L, Yan C, et al. A dual-targeting liposome enhances triple-negative breast cancer chemoimmunotherapy through inducing immunogenic cell death and inhibiting STAT3 activation[J]. Small, 2023, 19(40): e2302834.

[32] Naveed M, Hejazi V, Abbas M, et al. Chlorogenic acid (CGA): a pharmacological review and call for further research[J]. Biomed Pharmacother, 2018, 97: 67-74.

[33] Xue N, Zhou Q, Ji M, et al. Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype[J]. Sci Rep, 2017, 7: 39011.

[34] Zhu S, Li X, Luo Z, et al. Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy[J]. Drug Deliv Transl Res, 2024, 14(3): 718-729.

[35] Caldeira de ALS, Vinícius MeNM, Salviano TC, et al. Preparation, physicochemical characterization, and cell viability evaluation of long-circulating and pH-sensitive liposomes containing ursolic acid[J]. Biomed Res Int, 2013: 467147.

[36] Luo K, Yang L, Yan C, et al. A dual-targeting liposome enhances triple-negative breast cancer chemoimmunotherapy through inducing immunogenic cell death and inhibiting STAT3 activation[J]. Small, 2023, 19 (40): e2302834.

[37] Ma Q, Qian W, Tao W, et al. Delivery of curcumin nanoliposomes using surface modified with CD133 aptamers for prostate cancer[J]. Drug Des Devel Ther, 2019, 13: 4021-4033.

[38] Zhang L, Lin Z, Chen Y, et al. Co-delivery of docetaxel and resveratrol by liposomes synergistically boosts antitumor efficiency against prostate cancer[J]. Eur J Pharm Sci, 2022, 174106199-106199.

[39] Zhang X, Chen H, Zhang Y, et al. HA-DOPE-modified honokiol-loaded liposomes targeted therapy for osteosarcoma[J]. Int J Nanomedicine, 2022, 17: 5137-5151.

[40] Xia J, Ma S, Zhu X, et al. Versatile ginsenoside Rg3 liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches[J]. Sci Adv, 2022, 11; 8(6): eabj1262.

[41] Zheng Y, Kong F, Liu S, et al. Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy[J]. Drug Delivery, 2021, 28: 2033-2043

[42] Wang G, Yu Y, Wang YZ, et al. The effects and mechanisms of isoliquiritigenin loaded nanoliposomes regulated AMPK/mTOR mediated glycolysis in colorectal cancer[J]. Artif Cells Nanomed B, 2020, 48: 1231-1249

[43] Wu G, Li J, Yue J, et al. Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma[J]. Mol Med Rep, 2018, 17: 2456-2464.

[44] Li J, Zhou S, Yu J, et al. Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy[J]. J Control Release, 2021, 335: 306-319

[45] Song Y, Sheng Z, Xu Y, et al. Magnetic liposomal emodin composite with enhanced killing efficiency against breast cancer[J]. Biomater Sci, 2019, 7: 867-875

[46] Guo C, Su Y, Wang H, et al. A novel saponin liposomes based on the couplet medicines of platycodon grandiflorum-glycyrrhiza uralensis for targeting lung cancer[J]. Drug Deliv, 2022, 29 (1): 2743-2750.

[47] Yan YM, Zhang LM, Zhu HT, et al. Preparation of triptolide loaded liposomes by microfluidic method and preliminary study on their anti colon cancer effects[J]. Chin J Bioengineering, 2024, 44(10): 18-28.

[48] Kang S, Duan W, Zhang S, et al. Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma[J]. Theranostics, 2020, 10(10): 4308-4322.

[49] Kong YH, Zhang XP, Shi JB, et al. Preparation of tripterine loaded ginsenoside Rg3 liposome and experimental study on its targeting therapy for triple negative breast cancer[J]. Chin Herbal Med, 2024, 55(13): 4327-4337.

[50] Liu MM, Chen X, Qian JC, et al. Construction of triptolide prodrug liposome nano delivery system and evaluation of its anti pancreatic cancer activity[J]. Chin Pharm J, 2024, 59(10): 911-920.

[51] Li BM, Peng Y, Wang YL, et al. Clinical study of rhubarb ginseng formula in alleviating chemotherapy side effects and improving curative effect in patients with advanced gastrointestinal cancer[J]. Hb J TCM, 2015, 37(12): 1780-3 + 816

[52] Zhang FF, Qian KE, Malisha, et al. Preparation of ginsenoside Rg3 and rhein nanoemulsion and pharmacodynamic study of its combination with apd-l1 in the treatment of triple negative breast cancer[J]. Chin Med Mat, 2022, 53(16): 4973-4981

[53] Liu MJ, Qu D, Chen Y, et al. Preparation of novel butyryl galactose ester-modified coix component microemulsions and evaluation on hepatoma-targeting in vitro and in vivo[J]. Drug Deliv, 2016, 23(9): 3444-3451.

[54] Guo C, Guo D, Fang L, et al. Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon[J]. Carbohydr Polym, 2021, 267: 118231.

[55] Li W, Yalcin M, Lin Q, et al. Self-assembly of green tea catechin derivatives in nanoparticles for oral lycopene delivery[J]. J Control Release, 2017, 248: 117-24.

[56] Xu Q, Kong H, Ren S, et al. Coix seed oil alleviates synovial angiogenesis through suppressing HIF-1α/VEGF-A signaling pathways via SIRT1 in collagen-induced arthritis rats[J]. Chin Med, 2023, 18(1): 119.

[57] Chen Y, Qu D, Fu R, et al. A Tf-modified tripterine-loaded coix seed oil microemulsion enhances anti-cervical cancer treatment[J]. Int J Nanomed, 2018, 13: 7275-7287.

[58] Zeng H, Li X, Liu Y, et al. An icaritin-loaded microemulsion based on coix oil for improved pharmacokinetics and enhanced antitumor efficacy[J]. Drug Deliv, 2022, 29(1): 3454-3466.

[59] Qu D, Wang L, Liu M, et al. Correction to oral nanomedicine based on multicomponent microemulsions for drug-resistant breast cancer treatment[J]. Biomacromolecules, 2018, 19(3): 1090.

[60] Huang MM, Li P, Liu YP, et al. Preparation of triptolide coix seed microemulsion and its anti lung cancer effect in vivo[J]. World Sci Technol Mod Tradit Chin Med, 2017, 19(11): 1801-8.

[61] Qu D, Sun W, Liu M, et al. Bitargeted microemulsions based on coix seed ingredients for enhanced hepatic tumor delivery and synergistic therapy[J]. Int J Pharm, 2016, 503(1-2): 90-101.

[62] Yu Y, Shen M, Song Q, et al. Biological activities and pharmaceutical applications of polysaccharide from natural resources: a review[J]. Carbohydr Polym, 2018, 183: 91-101.

[63] Wang H, Zheng Y, Sun Q, et al. Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies[J]. J Nanobiotechnol, 2021, 19(1): 322.

[64] Zhang H, Zhang Y, Hu Y, et al. Improving cellular uptake and synergetic anti-tumor effects of magnolol and Brucea javanica oil through self-microemulsion[J]. Drug Dev Ind Pharm, 2024, 50(5): 401-409.

[65] Peng Y, Yu S, Wang Z, et al. Nanogels loading curcumin in situ through microemulsion photopolymerization for enhancement of antitumor effects[J]. J Mater Chem B, 2022, 10(17): 3293-3302.

[66] Li X, Yu L, Liu J, et al. Preparation and evaluation of huanglian ganjiang effective component self microemulsion drug delivery system[J]. Chin Tradit Herbal Drugs, 2023, 54(1): 51-60

[67] Hou Y, Zhu L, Zhang QY, et al. Preparation and in vivo intestinal absorption characteristics of rhubarb astragalus component self microemulsion[J]. Chin Tradit Herbal Drugs, 2023, 54(12): 3815-3823

[68] Yan Q, Xue YY, Li FQ, et al. Preparation and in vitro evaluation of a novel ionic liquid microemulsion of glycyrrhetinic acid[J]. Chin Tradit Herbal Drugse, 2023, 54(1): 63-70

[69] Wen J, Liu W, Song SY, et al. Evaluation of the targeted effect and protective effect of wu zhuyin phospholipid complex self microemulsiondrug delivery system on gastric ulcer[J]. Chin Tradit Herbal Drugs, 2024, 55(1): 171-180

[70] Rahdar A, Hajinezhad MR, Sargazi S, et al. Biochemical, ameliorative and cytotoxic effects of newly synthesized curcumin microemulsions: evidence fromin vitro andin vivo studies[J]. Nanomaterials, 2021, 11(3): 817.

[71] Xue S, Shen LS, Chen JY, et al. Study on the molecular mechanism of coix seed lipid submicron emulsion inducing iron death of pancreatic cancer cells based on non target metabolomics[J]. Chin Tradit Herbal Drugs, 2024, 55 (21): 7313-7324.

[72] Luo MY, Guan L, Lu S, et al. Study on the mechanism of anti proliferation of liver cancer cells by schisandrin B based on iron death pathway and its microemulsion enhanced effect[J]. Chin Tradit Herbal Drugs, 2024, 55(13): 4411-4422.

[73] Luo WV, Cao YJ, Wu E, et al. Antioxidant and anti A375 cell proliferation activities of Herba Anemarrhenae essential oil micro lotion[J]. Food Science, 2022, 43(09): 1-9.

[74] Lin L, Hong S, Li XW, et al. Effects of astragaloside IV and β-elemene on immunologic function of dentritic cells in rats[J]. J South Univ, 2011, 2011.

[75] Zhang MF.Oral pharmacokinetics and Caco-2 cell transport of ginsenoside Rg 3 phospholipid complex microemulsion in rats[D] Jilin: Jilin University, 2024.

[76] Perumal S, Atchudan R, Lee W. A Review of polymeric micelles and their applications[J]. Polymers (Basel), 2022, 14(12): 2510.

[77] Wang X, Zhang M, Li Y, et al. Research status of dendrimer micelles in tumor therapy for drug delivery[J]. Small, 2023, 19(50): e2304006.

[78] Hwang D, Ramsey JD, Kabanov AV. Polymeric micelles for the delivery of poorly soluble drugs: from nanoformulation to clinical approval[J]. Adv Drug Deliv Rev, 2020, 156: 80-118.

[79] Demina PA, Khaydukov KV, Babayeva G, et al. Upconversion nanoparticles intercalated in large polymer micelles for tumor imaging and chemo/photothermal therapy[J]. Int J Mol Sci, 2018, 24(3): 1090.

[80] Bhalani DV, Nutan B, Kumar A, et al. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics[J]. Biomedicines, 2022, 10(9): 2055

[81] Yadav BK, Patel R, Prajapati B, et al. Cutting-edge advances in nanocarrier-facilitated topical drug delivery systems for targeted skin cancer therapy: a comprehensive review[J]. Curr Pharm Biotechnol, 2024, 2024.

[82] Eid RK, Arafa MF, El Maghraby GM. Water in nigella oil microemulsion for enhanced oral bioavailability of linagliptin[J]. Drug Deliv Transl Res, 2024, 2024.

[83] Gou H, Huang RC, Zhang FL, et al. Design of dual targeting immunomicelles loaded with bufalin and study of their anti-tumor effect on liver cancer[J]. J Integr Med, 2021, 19(5): 408-417.

[84] Ji SP, Lin X, Yu EJ, et al. Curcumin-loaded mixed micelles: preparation, characterization, and in vitro antitumor aactivity[J]. J Nanotech, 2018, 3: 1-9.

[85] Do XH, Hoang MHT, Vu AT, et al. Differential cytotoxicity of curcumin-loaded micelles on human tumor and stromal cells[J]. Int J Mol Sci, 2022, 23(20): 12362.

[86] Lu Y, Miao L, Wang Y, et al. Curcumin mMicelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model[J]. Mol Ther, 2016, 24(2): 364-374.

[87] Xu L, Chen H, Xu H, et al. Anti-tumour and immuno-modulation effects of triptolide-loaded polymeric micelles[J]. Eur J Pharm Biopharm, 2008, 70(3): 741-748.

[88] Li M, Zhao Y, Sun J, et al. pH/reduction dual-responsive hyaluronic acid-podophyllotoxin prodrug micelles for tumor targeted delivery[J]. Carbohydr Polym, 2022, 288: 119402.

[89] Zhou M, Yi Y, Liu L, et al. Polymeric micelles loading with ursolic acid enhancing anti-tumor effect on hepatocellular carcinoma[J]. J Cancer, 2019, 10(23): 5820-5831.

[90] Liu R, Liu Z, Guo X, et al. Construction of curcumin-loaded micelles and evaluation of the anti-tumor effect based on angiogenesis[J]. Acupunct Herbal Med, 2023, 3(4): 343-356

[91] Guo F, Jiao Y, Ding W, et al. Synergistic effects of multidrug/material combination deliver system for anti-mutidrug-resistant tumor[J]. Int J Pharm, 2024, 649: 123669.

[92] Yuan Z, Yuan Y, Han L, et al. Bufalin-loaded vitamin E succinate-grafted-chitosan oligosaccharide/RGD conjugated TPGS mixed micelles demonstrated improved antitumor activity against drug-resistant colon cancer[J]. Int J Nanomed, 2018, 13: 7533-7548.

[93] Wang YZ, Liu DJ, Zhang D, et al. Triptolide combined with cyclopamine loaded in polymeric micelles: molecular dynamics, preparation andin vitro antitumor activities[J]. J Dispers Sci Technol, 2023, 2023, 2265964.

[94] Hou X, Ai X, Liu Z, et al. Wheat germ agglutinin modified mixed micelles overcome the dual barrier of mucus/enterocytes for effective oral absorption of shikonin and gefitinib[J]. Drug Deliv Transl Res, 2025, 15(1): 325-342.

[95] Zhang Q, Feng Z, Wang H, et al. Preparation of camptothecin micelles self-assembled from disodium glycyrrhizin and tannic acid with enhanced antitumor activity[J]. Eur J Pharm Biopharm, 2021, 164: 75-85.

[96] Liu F, Meng L, Wang H, et al. Research on preparation and antitumor activity of redox-responsive polymer micelles co-loaded with sorafenib and curcumin[J]. J Biomater Sci Polym Ed, 2023, 34(16): 2179-2197.

[97] Ma W, Guo Q, Li Y, et al. Co-assembly of doxorubicin and curcumin targeted micelles for synergistic delivery and improving anti-tumor efficacy[J]. Eur J Pharm Biopharm, 2017, 112: 209-223.

[98] Guo X, Zhao Z, Chen D, et al. Co-delivery of resveratrol and docetaxel via polymeric micelles to improve the treatment of drug-resistant tumors[J]. Asian J Pharm Sci, 2019, 14(1): 78-85.

[99] Fan Y, Marioli M, Zhang K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery[J]. J Pharm Biomed Anal, 2021, 192: 113642.

[100] Munson MJ, O'driscoll G, Silva AM, et al. A high-throughput Galectin-9 imaging assay for quantifying nanoparticle uptake, endosomal escape and functional RNA delivery[J]. Commun Biol, 2021, 4(1): 211.

[101] Aguilera-Garrido A, Arranz E, Gálvez-Ruiz MJ, et al. Solid lipid nanoparticles to improve bioaccessibility and permeability of orally administered maslinic acid[J]. Drug Deliv, 2022, 29(1): 1971-1982.

[102] Xia Y, Tang Y, Huang Z, et al. Artesunate-loaded solid lipid nanoparticles resist esophageal squamous cell carcinoma by inducing ferroptosis through inhibiting the AKT/mTOR signaling[J]. Cell Signal, 2024, 117: 111108.

[103] Alatawi HM, Alhwiti SS, Alsharif KA, et al. Nanostructured lipid carriers (NLCs) as effective drug delivery systems: methods of preparation and their therapeutic applications[J]. Recent Pat Nanotechnol, 2024, 18(2): 179-189.

[104] Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies[J]. Saudi Pharm J, 2021, 29(9): 999-1012.

[105] Yuan L, Liu C, Chen Y, et al. Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model[J]. Int J Nanomed, 2013, 8: 4339-4350.

[106] Zou Y, Huang B, Cao L, et al. Tailored mesoporous inorganic biomaterials: assembly, functionalization, and drug delivery engineering[J]. Adv Mater, 2021, 33(2): e2005215-e2005215.

[107] Wu M, Meng Q, Chen Y, et al. Large-pore ultrasmall mesoporous organosilica nanoparticles: micelle/precursor co-templating assembly and nuclear-targeted gene delivery[J]. Adv Mater, 2015, 27(2): 215-222.

[108] Chen W, Glackin CA, Horwitz MA, et al. Nanomachines and other caps on mesoporous silica nanoparticles for drug delivery[J]. Acc Chem Res, 2019, 52(6): 1531-1542.

[109] Slavin YN, Asnis J, Häfeli UO, et al. Metal nanoparticles: understanding the mechanisms behind antibacterial activity[J]. J Nanobiotechnol, 2017, 15(1): 65-65.

[110] Doyle AM, Shaikhutdinov SK, Jackson SD, et al. Hydrogenation on metal surfaces: why are nanoparticles more active than single crystals[J]. Angew Chem Int Ed Engl, 2003, 42: 5240-5243.

[111] Xiong PZ, Huang XM, Ye NJ, et al. Cytotoxicity of metal-based nanoparticles: from mechanisms and methods of evaluation to pathological manifestations[J]. Adv Sci (Weinh), 2022, 9(16): e2106049-e2106049.

[112] Nath D, Banerjee P. Green nanotechnology-a new hope for medical biology[J]. Environ Toxicol Pharmacol, 2013, 36(3): 997-1014.

[113] Huang YW, Cambre M, Lee HJ. The toxicity of nanoparticles depends on multiple molecular and physicochemical mechanisms[J]. Int J Mol Sci, 2017, 18(12): 2702.

[114] Gahlawat G, Choudhury AR. A review on the biosynthesis of metal and metal salt nanoparticles by microbes[J]. RSC Adv, 2019, 9(23): 12944-12967.

[115] Simões MF, Ottoni CA, Antunes A. Biogenic metal nanoparticles: a new approach to detect life on mars[J]. Life (Basel), 2020, 10(3): 28.

[116] Srivastava S, Usmani Z, Atanasov AG, et al. Biological nanofactories: using living forms for metal nanoparticle synthesis[J]. Mini Rev Med Chem, 2021, 21(2): 245-265.

[117] Ghosh S. Cisplatin: the first metal based anticancer drug[J]. Bioorg Chem, 2019, 88: 102925.

[118] Shi J, Votruba AR, Farokhzad OC, et al. Nanotechnology in drug delivery and tissue engineering: from discovery to applications[J]. Nano Lett, 2010, 10(9): 3223-3230.

[119] Qadri S, Abdulrehman T, Azzi J, et al. AgCuB nanoparticle eradicates intracellular S. aureus infection in bone cells: in vitro[J]. Emergent Materials, 2019, 2(2): 219-231.

[120] Parveen S, Misra R, Sahoo KS. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging[J]. Nanomedicine, 2011, 8(2): 147-166.

[121] Sara TA, Sarmadia A, Tahir A, et al. Synthesis and analysis of silver-copper alloy nanoparticles of different ratios manifest anticancer activity in breast cancer cells[J]. Cancer Nanotechnol, 2020, 11(1): 13.

[122] Liyanage PY, Hettiarachchi SD, Zhou Y, et al. Nanoparticle-mediated targeted drug delivery for breast cancer treatment[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871(2): 419-433.

[123] Thanki K, Gangwal RP, Sangamwar AT, et al. Oral delivery of anticancer drugs: challenges and opportunities[J]. J Control Release, 2013, 170(1): 15-40.

[124] Gao L, Liu G, Ma J, et al. Drug nanocrystals: in vivo performances[J]. J Control Release, 2012, 160(3): 418-430.

[125] Entezari M, Yousef Abad GG, Sedghi B, et al. Gold nanostructure-mediated delivery of anticancer agents: biomedical applications, reversing drug resistance, and stimuli-responsive nanocarriers[J]. Environ Res, 2023, 225: 115673-115673.

[126] Ren YS, Li HL, Piao XH, et al. Drug affinity responsive target stability (DARTS) accelerated small molecules target discovery: principles and application[J]. Biochem Pharmacol, 2021, 194: 114798.

[127] IJzerman AP, Guo D. Drug-target association kinetics in drug discovery[J]. Trends Biochem Sci, 2019, 44(10): 861-871.

[128] (a) Pauly CS, Genix AC, Alauzun JG, et al. Surface modification of alumina-coated silica nanoparticles in aqueous sols with phosphonic acids and impact on nanoparticle interactions[J]. Phys Chem Chem Phys, 2015, 17 (29): 19173-82.

[129] (b) Wang L, Xie YQ, Myrzagali, et al. Metal ions as effectual tools for cancer with traditional Chinese medicine[J]. Acupunct Herbal Med, 2023, 3 (4): 296-308.

[130] Li A, Gao W, Zhang X, et al. A dual-responsive “Yin-Yang” photothermal delivery system to accelerate Parthenolide anti-tumor efficacy[J]. Biomater Adv, 2022, 138: 212935.

[131] Mahalunkar S, Yadav AS, Gorain M, et al. Functional design of pH-responsive folate-targeted polymer-coated gold nanoparticles for drug delivery and in vivo therapy in breast cancer[J]. Int J Nanomed, 2019, 14, 8285-8302.

[132] Wu L, Pi W, Huang X, et al. Orchestrated metal-coordinated carrier-free celastrol hydrogel intensifies T cell activation and regulates response to immune checkpoint blockade for synergistic chemo-immunotherapy[J]. Biomaterials, 2025, 312 : 122723.

[133] Oh JY, Yang G, Choi E, et al. Mesoporous silica nanoparticle-supported nanocarriers with enhanced drug loading, encapsulation stability, and targeting efficiency[J]. Biomater Sci, 2022, 10(6): 1448-1455.

[134] McCarthy CA, Ahern RJ, Dontireddy R, et al. Mesoporous silica formulation strategies for drug dissolution enhancement: a review[J]. Expert Opin Drug Deliv, 2016, 13(1): 93-108.

[135] Li Z, Zhang Y, Feng N. Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery[J]. Expert Opin Drug Deliv, 2019, 16(3): 219-237.

[136] Šoltys M, Zůza D, Boleslavská T, et al. Drug loading to mesoporous silica carriers by solvent evaporation: a comparative study of amorphization capacity and release kinetics[J]. Int J Pharm, 2021, 607: 120982.

[137] Šoltys M, Kovačík P, Dammer O, et al. Effect of solvent selection on drug loading and amorphisation in mesoporous silica particles[J]. Int J Pharm, 2019, 555: 19-27.

[138] Jafari S, Derakhshankhah H, Alaei L, et al. Mesoporous silica nanoparticles for therapeutic/diagnostic applications[J]. Biomed Pharmacother, 2019, 109: 1100-1111.

[139] Abu-Dief AM, Alsehli M, Al-Enizi A, et al. Recent advances in mesoporous silica nanoparticles for targeted drug delivery applications[J]. Curr Drug Deliv, 2022, 19(4): 436-450.

[140] Kuang Y, Zhai J, Xiao Q, et al. Polysaccharide/mesoporous silica nanoparticle-based drug delivery systems: A review[J]. Int J Biol Macromol, 2021, 193: 457-473.

[141] Bernardos A, Piacenza E, Sancenón F, et al. Mesoporous silica-based materials with bactericidal properties[J]. Small, 2019, 15(24): e1900669.

[142] Li H, Zhu J, Xu YW, et al. Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction[J]. Redox Biol, 2022, 54: 102384.

[143] Zhang Z, Li W, Chang D, et al. A combination therapy for androgenic alopecia based on quercetin and zinc/copper dual-doped mesoporous silica nanocomposite microneedle patch[J]. Bioact Mater, 2022, 24: 81-95.

[144] Igaz N, Bélteky P, Kovács D, et al. Functionalized mesoporous silica nanoparticles for drug-delivery to multidrug-resistant cancer cells[J]. Int J Nanomed, 2022, 17: 3079-3096.

[145] Skwira A, Szewczyk A, Barros J, et al. Biocompatible antibiotic-loaded mesoporous silica/bioglass/collagen-based scaffolds as bone drug delivery systems[J]. Int J Pharm, 2023, 645: 123408.

[146] Li X, Li Y, Yu C, et al. ROS-responsive janus Au/mesoporous silica core/shell nanoparticles for drug delivery and long-Term CT imaging tracking of MSCs in pulmonary fibrosis treatment[J]. ACS Nano, 2023, 17(7): 6387-6399.

[147] An J, Chen C, Xu B, et al. Preparation of arginine-loaded mesoporous silica nanoparticles (Arg@MSNs) to improve the mechanical and antibacterial properties of denture base resin[J]. J Prosthet Dent, 2023, 131: 165. e1-165.e9.

[148] Li Z, Zhang Y, Zhu C, et al. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia[J]. Int J Pharm, 2020, 586: 119576.

[149] Li N, Wang Z, Zhang Y, et al. Curcumin-loaded redox-responsive mesoporous silica nanoparticles for targeted breast cancer therapy[J]. Artif Cells Nanomed Biotechnol, 2018, 46: 921-935.

[150] Wang M, Ma X, Wang G, et al. Targeting UBR5 in hepatocellular carcinoma cells and precise treatment via echinacoside nanodelivery[J]. Cell Mol Biol Lett, 2022, 27(1): 92-92.

[151] Feng Y, Li NX, Yin HL, et al. Thermo- and pH-responsive, lipid-coated, mesoporous silica nanoparticle-based dual drug delivery system to improve the antitumor effect of hydrophobic drugs[J]. Mol Pharm, 2019, 16(1): 422-436.

[152] Wu X, Yang H, Chen X, et al. Nano-herb medicine and PDT induced synergistic immunotherapy for colon cancer treatment[J]. Biomaterials, 2021, 269: 120654.

[153] Jiang Z, Wang Y, Sun L, et al. Dual ATP and pH responsive ZIF-90 nanosystem with favorable biocompatibility and facile post-modification improves therapeutic outcomes of triple negative breast cancer in vivo[J]. Biomaterials, 2019, 197: 41-50.

[154] Wu MX, Yang YW. Metal-organic framework (MOF)-based drug/cargo delivery and cancer therapy[J]. Adv Mater, 2017, 29 (23).

[155] Zhou G, Li M. Near-infrared-II plasmonic trienzyme-integrated metal-organic frameworks with high-efficiency enzyme cascades for synergistic trimodal oncotherapy[J]. Adv Mater, 2022, 34(24): e2200871.

[156] Ohshima K, Ohsaki S, Nakamura H, et al. Mechanism of solubility enhancement of poorly water-soluble drugs triggered by zeolitic imidazolate frameworks[J]. Chem Pharm Bull (Tokyo), 2022, 70(5): 383-390.

[157] Wang WJ, Zhang L, Deng QQ, et al. Yeast@MOF bioreactor as a tumor metabolic symbiosis disruptor for the potent inhibition of metabolically heterogeneous tumors[J]. Nano Today, 2022, 101331: 1748.

[158] Deneff JI, Butler KS, Kotula PG, et al. Expanding the ZIFs repertoire for biological applications with the targeted synthesis of ZIF-20 nanoparticles[J]. ACS Appl Mater Interfaces, 2021, 13(23): 27295-27304.

[159] Parsaei M, Akhbari K. Synthesis and application of MOF-808 decorated with folic acid-conjugated chitosan as a strong nanocarrier for the targeted drug delivery of quercetin[J]. Inorg Chem, 2022, 61(48): 19354-19368.

[160] Guo H, Liu Y, Li X, et al. Magnetic metal-organic framework-based nanoplatform with platelet membrane coating as a synergistic programmed cell death protein 1 inhibitor against hepatocellular carcinoma[J]. ACS Nano, 2023, 17(23): 23829-23849.

[161] Zeng H, Xia C, Zhao B, et al. Folic acid-functionalized metal-organic framework nanoparticles as drug carriers improved bufalin antitumor activity against breast cancer[J]. Front Pharmacol, 2022, 12: 747992.

[162] Zhou R, You Y, Zha Z, et al. Biotin decorated celastrol-loaded ZIF-8 nano-drug delivery system targeted epithelial ovarian cancer therapy[J]. Biomed Pharmacother, 2023, 167: 115573-115573.

[163] Guo H, Li X, Mao D, et al. Homologous-magnetic dual-targeted metal-organic framework to improve the anti-hepatocellular carcinoma efficacy of PD-1 inhibitor[J]. J Nanobiotechnol, 2024, 22(1): 206-206.

[164] O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.[J]. Ann Oncol, 2004, 15(3): 440-449.

[165] Konstantin S, Dominik K, Florian H, et al. Non-pegylated liposomal doxorubicin as palliative chemotherapy in pre-treated advanced pancreatic cancer: a retrospective analysis of twenty-eight patients[J]. Technol Cancer Res Treat, 2021, 20: 15330338211042139-15330338211042139.

[166] Athanasios F, Achilles A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.[J]. Leukemia & lymphoma, 2005, 46(6): 795-802.

[167] Herzog C, Hartmann K, Künzi V, et al. Eleven years of inflexal ® V—a virosomal adjuvanted influenza vaccine[J]. Vaccine, 2009, 27(33): 4381-4387.

[168] Ilfeld BM, Eisenach JC, Gabriel RA. Clinical effectiveness of liposomal bupivacaine administered by infiltration or peripheral nerve block to treat postoperative pain.[J]. Anesthesiology, 2020, 134(2): 283-344.

[169] Valerie W, Felix R. Inhaled liposomal amikacin.[J]. Expert Rev Respir Med, 2014, 8(4): 401-409.

[170] Stone NR, Bicanic T, Salim R, et al. Liposomal amphotericin B (AmBisome(®)): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions[J]. Drugs, 2016, 76(4): 485-500.

[171] Simon JA. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.[J]. Menopause, 2006, 13(2): 222-231.

[172] Manuel R, Pilar B, Stefano B, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies.[J]. Ann Rheum Dis, 2020, 79(1): 3-18.

[173] Tynes BE, Johnson CD, Vaish MH, et al. Ketoconazole shampoo for seborrheic dermatitis of the scalp: a narrative review[J]. Cureus, 2024, 16(8): e67532.

[174] Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group [J]. Ophthalmology, 2000, 107( 4): 631-639.

[175] Tsang K, Zhong NS. Sars: pharmacotherapy[J]. Respirology, 2003, 8: 25-30.

[176] Ok SK, Hee YL, Wei SJ, et al. Genexol (R)-PM, a polymeric micellar paclitaxel formulation, suppresses primary tumor growth and metastasis in a green fluorescent protein orthotopic model of breast and pancreatic cancers[J]. Cancer Res, 2006, 66 (8).

[177] Wei X, Liu L, Li X, et al. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy[J]. J Control Release, 2019, 313: 42-53.

Funding

National Natural Science Foundation of China(82374045)

National Natural Science Foundation of China(82173985)

Jiangsu Province Leading Talent Project(CZ2023SLJ0302)

National Natural Science Foundation of China(82173980)

Jiangsu Province Key Research and Development Program for Social Development Project(BE2023788)

Jiangsu Clinical Innovation Center of Digestive Cancer of Traditional Chinese Medicine(2021.6)